LLY

745.81

-0.47%↓

JNJ

175.13

-0.96%↓

ABBV

210.33

+0.37%↑

UNH

344.5

-0.1%↓

AZN

80.7

-0.42%↓

LLY

745.81

-0.47%↓

JNJ

175.13

-0.96%↓

ABBV

210.33

+0.37%↑

UNH

344.5

-0.1%↓

AZN

80.7

-0.42%↓

LLY

745.81

-0.47%↓

JNJ

175.13

-0.96%↓

ABBV

210.33

+0.37%↑

UNH

344.5

-0.1%↓

AZN

80.7

-0.42%↓

LLY

745.81

-0.47%↓

JNJ

175.13

-0.96%↓

ABBV

210.33

+0.37%↑

UNH

344.5

-0.1%↓

AZN

80.7

-0.42%↓

LLY

745.81

-0.47%↓

JNJ

175.13

-0.96%↓

ABBV

210.33

+0.37%↑

UNH

344.5

-0.1%↓

AZN

80.7

-0.42%↓

Search

Innoviva Inc

Abrir

SetorSaúde

19.92 -1.19

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.85

Máximo

20.29

Indicadores-chave

By Trading Economics

Rendimento

110M

64M

Vendas

12M

100M

P/E

Médio do Setor

35.895

35.733

Margem de lucro

63.508

Funcionários

127

EBITDA

111M

84M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+99.45% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

124M

1.3B

Abertura anterior

21.11

Fecho anterior

19.92

Sentimento de Notícias

By Acuity

28%

72%

74 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Innoviva Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de set. de 2025, 23:37 UTC

Ações em Alta

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 de set. de 2025, 20:41 UTC

Ganhos

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 de set. de 2025, 20:30 UTC

Ganhos

GameStop 2Q Sales, Profit Rise

9 de set. de 2025, 23:19 UTC

Conversa de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 de set. de 2025, 21:35 UTC

Ganhos

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 21:32 UTC

Ganhos

Oracle's Backlog Swells With Big Customer Deals -- Update

9 de set. de 2025, 21:02 UTC

Aquisições, Fusões, Aquisições de Empresas

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de set. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 de set. de 2025, 20:26 UTC

Ganhos

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 20:23 UTC

Ganhos

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 de set. de 2025, 20:12 UTC

Ganhos

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 de set. de 2025, 20:10 UTC

Ganhos

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 de set. de 2025, 20:10 UTC

Ganhos

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 de set. de 2025, 20:09 UTC

Ganhos

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 de set. de 2025, 20:09 UTC

Ganhos

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 de set. de 2025, 20:08 UTC

Ganhos

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 de set. de 2025, 20:07 UTC

Ganhos

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 de set. de 2025, 20:06 UTC

Ganhos

Oracle 1Q Software Revenue $5.72B >ORCL

9 de set. de 2025, 20:06 UTC

Ganhos

Synopsys 3Q Adj EPS $3.39 >SNPS

9 de set. de 2025, 20:06 UTC

Ganhos

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Rev $14.93B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q EPS $1.01 >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Synopsys 3Q EPS $1.50 >SNPS

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Services Revenue $1.35B >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Adj EPS $1.47 >ORCL

9 de set. de 2025, 20:05 UTC

Ganhos

Oracle 1Q Hardware Revenue $670M >ORCL

Comparação entre Pares

Variação de preço

Innoviva Inc Previsão

Preço-alvo

By TipRanks

99.45% parte superior

Previsão para 12 meses

Média 40.25 USD  99.45%

Máximo 55 USD

Mínimo 26 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Innoviva Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

18.57 / 18.75Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

74 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat